Legend Biotech enters its third-quarter report carrying a milestone it spent years promising: last quarter it turned a profit on both a reported and adjusted basis for the first time. The harder question now is durability. Management has already warned that gross margin will slip back from the prior quarter's flattered level, a new tax burden has arrived, and the chief executive who led the company to profitability has departed. This report will show whether the earnings story survives those headwinds or whether the second quarter was a high-water mark that will take time to revisit.
The Street is setting a low bar on the bottom line. Consensus calls for earnings of about a penny a share on revenue of roughly $359.9 million. That revenue figure would mark growth of about 32% from the $272.3 million reported a year ago and a swing from a loss of 11 cents. It also sits below the $387.5 million Legend posted last quarter, so analysts are effectively modeling a sequential step down. The whisper number of 4 cents is a bit above consensus. In absolute terms the gap is small, but on an estimate this close to breakeven it signals that some investors expect Legend to stay comfortably in the black rather than drifting back toward zero.
The operating driver remains Carvykti, the BCMA-directed CAR-T therapy Legend shares with Johnson & Johnson. Net trade sales have climbed every quarter, from $524 million a year earlier to $657 million last quarter, a 50% annual gain, with ex-US sales more than doubling. Just as important, more than 70% of use now comes in second through fourth lines of therapy, up from 60% a year earlier. Treatment sites reached 348 worldwide. Another sequential rise in Carvykti sales, along with steady or rising earlier-line share, would validate management's claim that the franchise is still in its expansion phase. A flat quarter would invite tougher questions, particularly with bispecific antibodies posting striking trial data and a rival CAR-T potentially approaching launch. Management argues those threats mainly target later lines, so earlier-line mix is the best real-time test of that argument.
Margins are where the profit story could wobble. Gross margin on product sales has bounced from 57% to 41% to 58% across recent quarters, and management guided the current quarter back to the low 50s, noting that last quarter benefited from a few points of one-time favorability. A rising outpatient mix, now around 60%, brings different cost dynamics. Results landing in that low-50s range would show the company understands its cost structure. Anything meaningfully lower would suggest variability is structural rather than episodic. Add a tax rate expected in the high 20s and the path from revenue growth to earnings becomes narrower than the top line implies.
Beyond the numbers, the call should address the CEO search, which management framed as a leadership change rather than a strategic one, and progress on the in vivo CAR-T platform. Early LB2501 data showed every patient responding at the second dose level, and the company targeted a US filing to begin trials by year-end. Confirmation that the timeline holds, plus any color on the newly disclosed BCMA in vivo program, would support the case that the $212 million equity raise is funding real momentum.
Sentiment has improved sharply, moving from clearly bearish before the last report to modestly bullish now, yet the stock has done little, slipping about 3% and roughly matching the S&P 500. At $21.10 it trades below its 200-day average of $22.13 but well off its post-report low of $16.86, a far calmer range than the plunge from $37.50 the prior quarter. Ultimately, the report hinges on whether Carvykti growth can outrun the margin reset and tax drag enough to keep Legend profitable without one-time help.